Bristol-Myers Squibb Company (BMY)
Quick ratio
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 11,464,000 | 9,123,000 | 13,979,000 | 14,546,000 | 12,346,000 |
| Short-term investments | US$ in thousands | 1,275,000 | 1,234,000 | 5,006,000 | 4,737,000 | 5,242,000 |
| Receivables | US$ in thousands | 10,921,000 | 9,886,000 | 9,369,000 | 8,501,000 | 7,685,000 |
| Total current liabilities | US$ in thousands | 22,262,000 | 21,890,000 | 21,868,000 | 19,080,000 | 18,304,000 |
| Quick ratio | 1.06 | 0.92 | 1.30 | 1.46 | 1.38 |
December 31, 2023 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($11,464,000K
+ $1,275,000K
+ $10,921,000K)
÷ $22,262,000K
= 1.06
The quick ratio of Bristol-Myers Squibb Co. has shown some variability over the past five years. In 2023, the quick ratio stands at 1.31, indicating that the company has $1.31 of liquid assets available to cover each dollar of current liabilities. This suggests that the company has improved its ability to meet short-term obligations with its liquid assets compared to the previous year, where the quick ratio was 1.13.
Looking back at the trend, the quick ratio was relatively high in 2021 at 1.42 and 2020 at 1.47, indicating a strong liquidity position during those years. In 2019, the quick ratio was 1.37, which was also considered healthy.
Overall, while the quick ratio has fluctuated year on year, the company has generally maintained a solid ability to meet its short-term obligations with its liquid assets. However, it is important to note that a quick ratio above 1.0 indicates the company's ability to cover its current liabilities, but it is also essential to consider the industry standards and specific business circumstances for a more comprehensive analysis.
Peer comparison
Dec 31, 2023